Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5198557
Max Phase: Preclinical
Molecular Formula: C60H67BF2N12O9S
Molecular Weight: 1181.15
Associated Items:
ID: ALA5198557
Max Phase: Preclinical
Molecular Formula: C60H67BF2N12O9S
Molecular Weight: 1181.15
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cn1cc(COc2ccc(/C=C/C3=[N+]4C(=Cc5ccc(-c6cccs6)n5[B-]4(F)F)C=C3)cc2)nn1)C(N)=O
Standard InChI: InChI=1S/C60H67BF2N12O9S/c1-38(2)56(69-55(78)26-29-72-27-24-47(25-28-72)84-52-12-7-6-11-41(52)31-40-9-4-3-5-10-40)60(82)68-50(36-76)59(81)66-48(33-54(64)77)58(80)67-49(57(65)79)35-73-34-42(70-71-73)37-83-46-21-15-39(16-22-46)14-17-43-18-19-44-32-45-20-23-51(53-13-8-30-85-53)75(45)61(62,63)74(43)44/h3-23,30,32,34,38,47-50,56,76H,24-29,31,33,35-37H2,1-2H3,(H2,64,77)(H2,65,79)(H,66,81)(H,67,80)(H,68,82)(H,69,78)/b17-14+/t48-,49-,50-,56-/m0/s1
Standard InChI Key: VSFZOXZGJPFVLR-RQZICYRLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1181.15 | Molecular Weight (Monoisotopic): 1180.4936 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):